<DOC>
	<DOCNO>NCT00655733</DOCNO>
	<brief_summary>Double-blind , randomize , multicenter , placebo-controlled study The purpose study evaluate efficacy safety HMPL-004 patient active moderate Crohn 's Disease , compare placebo .</brief_summary>
	<brief_title>Phase II Study HMPL-004 Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Have active confirm Crohn 's Disease ( confirm radiographically , endoscopic , histologically ) , CDAI 220400 baseline screen They receive antiTNFÎ± antibody within 3 month start study medication , cyclosporine , tacrolimus , thalidomide mycophenolate mofetil within 2 month start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>